NCT06223542
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-hodgkin Lymphoma, +8 more
- Locations
-
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
Clinical trial condition
Indolent Non-hodgkin Lymphoma
Explore clinical trials studying Indolent Non-hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.
24 public trials
4 recruiting studies
Indolent Non-hodgkin Lymphoma trial results
NCT05876923
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Disease Attributes, +15 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
NCT04883437
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +18 more
- Locations
-
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
- Conditions
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Follicular Lymphoma, Hemic and Lymphatic Diseases, +16 more
- Locations
-
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, North Carolina, United States
Not yet recruiting
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
NCT06557330
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
- Locations
-
Not specified
Active, not recruiting
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
NCT03198026
- Conditions
- Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, +26 more
- Locations
-
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Philadelphia, Pennsylvania, United States
Active, not recruiting
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
NCT05783596
- Conditions
- Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
- Locations
-
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Columbia University Irving Medical Center New York, United States
- Mount Sinai Medical Center New York, United States
Active, not recruiting
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT03749018
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, +22 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, not recruiting
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
NCT04323956
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, +22 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Active, not recruiting
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
NCT03884998
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, +26 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- OHSU Knight Cancer Institute Portland, Oregon, United States